Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
We screened for drugs that activate the Runx2 promoter and identified that lansoprazole, a proton pump inhibitor, upregulated the Runx2 activity. Lansoprazole elevated expression levels of Runx2 mRNA and protein in osteoblast-lineage cells in a dose-dependent manner. Lansoprazole exerted an increase of ALP and Osterix activities in osteoblast-lineage cells. Lansoprazole accelerated the matrix calcium deposition in human bone marrow derived osteoprogenitors. Systemic administration of lansoprazole to a rat fracture model increased osteoblastic parameters and facilitated fracture healing. We propose that lansoprazole holds promise as a therapeutic agent for bone regeneration at fracture sites.
|